标题
Adjuvant Chemotherapy for Stage III Colon Cancer
作者
关键词
-
出版物
Cancers
Volume 12, Issue 9, Pages 2679
出版商
MDPI AG
发表日期
2020-09-21
DOI
10.3390/cancers12092679
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study
- (2020) F. Pagès et al. ANNALS OF ONCOLOGY
- “Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial”
- (2020) Julien Taïeb et al. DIGESTIVE AND LIVER DISEASE
- Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
- (2020) Thierry Conroy et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.
- (2020) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
- (2020) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives
- (2019) Julien Taieb et al. CANCER TREATMENT REVIEWS
- FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.
- (2019) Matthew T. Seymour et al. JOURNAL OF CLINICAL ONCOLOGY
- Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).
- (2019) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.
- (2019) David Lau et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
- (2019) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
- (2019) J Taieb et al. ANNALS OF ONCOLOGY
- Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers
- (2019) M. Karoui et al. ANNALS OF SURGERY
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration
- (2019) J Taieb et al. ANNALS OF ONCOLOGY
- Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
- (2019) N Tarazona et al. ANNALS OF ONCOLOGY
- Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study
- (2019) Cynthia Reichling et al. GUT
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
- (2019) Jeanne Tie et al. JAMA Oncology
- Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
- (2018) Peng Gao et al. BMC CANCER
- Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy
- (2018) Claire Gallois et al. CLINICAL CANCER RESEARCH
- Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK)
- (2018) Pierre Michel et al. DIGESTIVE AND LIVER DISEASE
- Delay in Adjuvant Chemotherapy and Survival Advantage in Stage III Colon Cancer
- (2018) Megan C. Turner et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- 60PDColon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8
- (2018) P Laurent-Puig et al. ANNALS OF ONCOLOGY
- Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI-PRODIGE Trial
- (2018) Jaafar Bennouna et al. Clinical Colorectal Cancer
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review
- (2017) Gaowei Fan et al. PLoS One
- Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients
- (2016) J. Taieb et al. ANNALS OF ONCOLOGY
- Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
- (2016) P. Yan et al. CLINICAL CANCER RESEARCH
- Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer
- (2016) Alexandra Lapeyre-Prost et al. Clinical Colorectal Cancer
- PRODIGE 34 – FFCD 1402 – ADAGE
- (2016) Thomas Aparicio et al. DIGESTIVE AND LIVER DISEASE
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
- (2016) David Tougeron et al. JNCI-Journal of the National Cancer Institute
- Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
- (2016) Rachel S Kerr et al. LANCET ONCOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
- (2016) Piero Dalerba et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
- (2016) David Tougeron et al. JNCI-Journal of the National Cancer Institute
- Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials
- (2015) D. G. Haller et al. ANNALS OF ONCOLOGY
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer
- (2015) Margaret M Kozak et al. JOURNAL OF CLINICAL PATHOLOGY
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway
- (2014) B Zhang et al. BRITISH JOURNAL OF CANCER
- Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
- (2014) D. Mouradov et al. CANCER RESEARCH
- CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer
- (2014) Stacey Shiovitz et al. GASTROENTEROLOGY
- Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data
- (2014) Antonio F. Di Narzo et al. JNCI-Journal of the National Cancer Institute
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
- (2014) Julien Taieb et al. LANCET ONCOLOGY
- Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database
- (2013) Nadine J. McCleary et al. JOURNAL OF CLINICAL ONCOLOGY
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581
- (2013) Alan P. Venook et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer
- (2013) Enric Domingo et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
- (2013) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis
- (2013) Jia-Xing Zhang et al. LANCET ONCOLOGY
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis
- (2012) Trude H Ågesen et al. GUT
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
- (2012) Daniel J. Sargent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years
- (2012) Hanna K. Sanoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival
- (2012) Xiaoyun Liao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer
- (2011) H. J. Chang et al. ANNALS OF ONCOLOGY
- Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
- (2011) A. Zaanan et al. CLINICAL CANCER RESEARCH
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
- (2011) Richard D. Kennedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
- (2011) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
- (2011) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis
- (2010) Gaetan Des Guetz et al. EUROPEAN JOURNAL OF CANCER
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
- (2009) M. Ychou et al. ANNALS OF ONCOLOGY
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)
- (2008) Ivan Popov et al. EUROPEAN JOURNAL OF CANCER
- Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon Cancer
- (2008) Yuqiu Jiang et al. JOURNAL OF MOLECULAR DIAGNOSTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now